634 related articles for article (PubMed ID: 23518659)
1. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
[TBL] [Abstract][Full Text] [Related]
2. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.
Cole LE; Li L; Jetley U; Zhang J; Pacheco K; Ma F; Zhang J; Mundle S; Yan Y; Barone L; Rogers C; Beltraminelli N; Quemeneur L; Kleanthous H; Anderson SF; Anosova NG
Vaccine; 2019 Jun; 37(29):3892-3901. PubMed ID: 31122858
[TBL] [Abstract][Full Text] [Related]
4. Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting.
Quemeneur L; Petiot N; Arnaud-Barbe N; Hessler C; Pietrobon PJ; Londoño-Hayes P
Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29632249
[No Abstract] [Full Text] [Related]
5. A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.
Anosova NG; Cole LE; Li L; Zhang J; Brown AM; Mundle S; Zhang J; Ray S; Ma F; Garrone P; Bertraminelli N; Kleanthous H; Anderson SF
Clin Vaccine Immunol; 2015 Jul; 22(7):711-25. PubMed ID: 25924765
[TBL] [Abstract][Full Text] [Related]
6. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
[TBL] [Abstract][Full Text] [Related]
7. Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.
Wang Y; Wang S; Bouillaut L; Li C; Duan Z; Zhang K; Ju X; Tzipori S; Sonenshein AL; Sun X
Infect Immun; 2018 Nov; 86(11):. PubMed ID: 30150259
[TBL] [Abstract][Full Text] [Related]
8. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.
Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC
Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987
[TBL] [Abstract][Full Text] [Related]
9. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers.
Bézay N; Ayad A; Dubischar K; Firbas C; Hochreiter R; Kiermayr S; Kiss I; Pinl F; Jilma B; Westritschnig K
Vaccine; 2016 May; 34(23):2585-92. PubMed ID: 27079932
[TBL] [Abstract][Full Text] [Related]
10. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters.
Giannasca PJ; Zhang ZX; Lei WD; Boden JA; Giel MA; Monath TP; Thomas WD
Infect Immun; 1999 Feb; 67(2):527-38. PubMed ID: 9916055
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.
Torres JF; Lyerly DM; Hill JE; Monath TP
Infect Immun; 1995 Dec; 63(12):4619-27. PubMed ID: 7591115
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC.
Ghose C; Eugenis I; Sun X; Edwards AN; McBride SM; Pride DT; Kelly CP; Ho DD
Emerg Microbes Infect; 2016 Feb; 5(2):e8. PubMed ID: 26839147
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease.
Ghose C; Verhagen JM; Chen X; Yu J; Huang Y; Chenesseau O; Kelly CP; Ho DD
Infect Immun; 2013 Jun; 81(6):2190-6. PubMed ID: 23545305
[TBL] [Abstract][Full Text] [Related]
14. Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model.
Heidebrecht HJ; Weiss WJ; Pulse M; Lange A; Gisch K; Kliem H; Mann S; Pfaffl MW; Kulozik U; von Eichel-Streiber C
Toxins (Basel); 2019 Feb; 11(2):. PubMed ID: 30736358
[TBL] [Abstract][Full Text] [Related]
15. Immunogenic properties of the surface layer precursor of Clostridium difficile and vaccination assays in animal models.
Bruxelle JF; Mizrahi A; Hoys S; Collignon A; Janoir C; Péchiné S
Anaerobe; 2016 Feb; 37():78-84. PubMed ID: 26505926
[TBL] [Abstract][Full Text] [Related]
16. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
[TBL] [Abstract][Full Text] [Related]
17. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.
Guo S; Yan W; McDonough SP; Lin N; Wu KJ; He H; Xiang H; Yang M; Moreira MA; Chang YF
Vaccine; 2015 Mar; 33(13):1586-95. PubMed ID: 25698490
[TBL] [Abstract][Full Text] [Related]
18. An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.
Baliban SM; Michael A; Shammassian B; Mudakha S; Khan AS; Cocklin S; Zentner I; Latimer BP; Bouillaut L; Hunter M; Marx P; Sardesai NY; Welles SL; Jacobson JM; Weiner DB; Kutzler MA
Infect Immun; 2014 Oct; 82(10):4080-91. PubMed ID: 25024365
[TBL] [Abstract][Full Text] [Related]
19. A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters.
Wang YK; Yan YX; Kim HB; Ju X; Zhao S; Zhang K; Tzipori S; Sun X
Hum Vaccin Immunother; 2015; 11(9):2215-22. PubMed ID: 26036797
[TBL] [Abstract][Full Text] [Related]
20. A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults.
Sheldon E; Kitchin N; Peng Y; Eiden J; Gruber W; Johnson E; Jansen KU; Pride MW; Pedneault L
Vaccine; 2016 Apr; 34(18):2082-91. PubMed ID: 26993331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
